nasopharyngeal type undifferentiated carcinoma
nasopharyngeal type undifferentiated carcinoma
Explore linked clinical trials. Standard reference: MONDO:00035722 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Myosarcoma, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Recurrence, Stomatognathic Diseases, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, carcinoma, epithelial neoplasm, glioma, head and neck squamous cell carcinoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, medulloblastoma, mixed neoplasm, myomatous neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, nasopharyngeal type undifferentiated carcinoma, neoplasm, neuroblastoma, neuroepithelial neoplasm, otorhinolaryngologic disease, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, squamous cell carcinoma, urinary system disorder | Recruiting | Phase 1 | 2026-05-13 | NCT07584499 | |
| Safety and Efficacy of Pucotenlimab in pLECC | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, nasopharyngeal type undifferentiated carcinoma, neoplasm | Recruiting | Phase 2 | 2025-05-15 | NCT06969534 |